Insud Pharma and Fresenius Kabi combine efforts to accelerate the growth of mAbxience
Under the terms of the agreement Fresenius Kabi will acquire 55% of mAbxience, the global fully-fledged biotech company of the Spanish group.
- Under the terms of the agreement Fresenius Kabi will acquire 55% of mAbxience, the global fully-fledged biotech company of the Spanish group.
- "We're delighted to announce our combination with Fresenius Kabi for the future development of mAbxience.
- As joint partners with Fresenius Kabi, we fully expect to further accelerate our mission to deliver affordable medicines to patients worldwide."
- Emmanuelle Lepine, mAbxience CEO, said, "We believe this new strategic partnership with Fresenius Kabi represents the best possible next step in line with mAbxiences strategic growth plan.